Assignee profile:

Corvus Pharmaceuticals, Inc.

City:

Burlingame, California

Country:

United States

Published Applications:

15

Last publication date:

2022-11-17

Patent Grants:

15

Last grant date:

2024-02-13

Top Inventors for applications by Corvus Pharmaceuticals, Inc.

These are the the leading inventors for applications assigned to Corvus Pharmaceuticals, Inc.:

Recent patent applications by Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. based in Burlingame, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-11-17 ✅ Patent 11,897,874 granted on 2024-02-13
US20220363676A1
Chemistry; metallurgy

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

#2 | 2022-02-22 ✅ Patent 11,254,686 granted on 2022-02-22
US16640508
Chemistry; metallurgy

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

#3 | 2021-08-19 ✅ Patent 12,174,192 granted on 2024-12-24
US20210255190A1
Physics

Methods for detecting and treating cancers having adenosine pathway activation

#4 | 2021-08-19 ✅ Patent 12,116,635 granted on 2024-10-15
US20210254178A1
Chemistry; metallurgy

Methods for detecting and treating cancers having adenosine pathway activation

#5 | 2021-08-19 ✅ Patent 11,859,007 granted on 2024-01-02
US20210253727A1
Chemistry; metallurgy

Humanized anti-CD73 antibodies

#6 | 2021-07-22 ✅ Patent 12,351,644 granted on 2025-07-08
US20210221905A1
Chemistry; metallurgy

ANTI-CD73 ANTIBODIES

#7 | 2021-05-27 ✅ Patent 12,023,337 granted on 2024-07-02
US20210154199A1
Human necessities

Methods of treating cancer

#8 | 2021-03-04 ✅ Patent 11,266,649 granted on 2022-03-08
US20210060020A1
Human necessities

Pharmaceutical formulations

#9 | 2020-09-24 ✅ Patent 11,040,040 granted on 2021-06-22
US20200297728A1
Human necessities

Methods of treating cancer

#10 | 2019-12-12 ✅ Patent 11,008,314 granted on 2021-05-18
US20190375743A1
Chemistry; metallurgy

Compounds and methods for modulating interleukin-2-inducible t-cell kinase

#11 | 2019-04-11 ✅ Patent 10,870,652 granted on 2020-12-22
US20190106423A1
Chemistry; metallurgy

Compounds and methods for modulating bruton's tyrosine kinase

#12 | 2019-03-14 ✅ Patent 10,822,426 granted on 2020-11-03
US20190077873A1
Chemistry; metallurgy

Humanized anti-CD73 antibodies

#13 | 2019-03-14 ✅ Patent 10,912,776 granted on 2021-02-09
US20190076433A1
Human necessities

Methods of treating cancer

#14 | 2018-10-11 ✅ Patent 10,654,825 granted on 2020-05-19
US20180290999A1
Chemistry; metallurgy

Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof

#15 | 2018-01-11 ✅ Patent 10,793,636 granted on 2020-10-06
US20180009899A1
Chemistry; metallurgy

Anti-CD73 antibodies

Also check out Corvus Pharmaceuticals, Inc.'s (Burlingame, United States) applicant profile with 19 patent applications submitted.

AssigneeID:

307971 ⎘